Search results
Results from the WOW.Com Content Network
AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]
The drug, marketed under the name Imdelltra, is part of Amgen's pipeline of bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body's ...
(Reuters) -Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting the main goal of ...
(Reuters) -Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert ...
Panitumumab has been associated with skin rash, fatigue, nausea, diarrhea, fever, and decreased magnesium levels. Often, skin rash is noted in the sun exposed parts of the body, such as the face or chest. Oral antibiotics may be needed for worsening skin rash, such as one accompanied with blisters and ulcers.
Since October 2023, Amgen Inc. has been the marketer of pegloticase in the U.S. It was developed by Savient Pharmaceuticals . [ 3 ] [ 4 ] It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.
With its current products and others in development, including cancer and rare disease drugs, Amgen is looking at "solid mid-single-digit growth, although clearly an obesity win could move this ...
The applicant for this medicinal product is Amgen Technology (Ireland) Unlimited Company. [50] Bekemv is a biosimilar medicinal product. [50] It is highly similar to the reference product Soliris (eculizumab), which was authorized in the EU on 20 June 2007. [50] Data show that Bekemv has comparable quality, safety and efficacy to Soliris. [50]